Samsung Biologics establishes first U.S. manufacturing base with acquisition of GSK site – Chemical Engineering

April 3, 2026 | By Mary Bailey

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.

The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters.

Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics also plans further investments to expand the site’s capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines.

“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family,” said John Rim, President and CEO of Samsung Biologics. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.”

The completion follows the previously announced agreement to acquire the facility on December 22, 2025.

Source link

Samsung Biologics secures first manufacturing base in U.S.

Samsung Biologics Co. has expanded its global production network by securing its first manufacturing base in the United States.

Samsung Biologics announced on Wednesday that it completed the acquisition of a biopharmaceutical production facility in Rockville, Maryland, previously owned by GSK Plc, as of Tuesday, local time. The deal was carried out through its subsidiary, Samsung Biologics America.

The Rockville site is a drug substance (DS) manufacturing plant with total capacity of 60,000 liters, comprising two production buildings. It is equipped with infrastructure capable of producing antibody therapeutics at various scales, from clinical-stage to commercial production.

With this acquisition, Samsung Biologics has expanded its total production capacity to 845,000 liters from 785,000 liters. The company said that it has now established a dual production system connecting Songdo, Korea, and Rockville, enabling more stable and flexible supply to global clients.

In particular, securing a production base in North America is expected to strengthen responsiveness to local customers and further enhance competitiveness in winning global contracts.

Samsung Biologics has retained all approximately 500 employees at the Rockville facility, ensuring operational continuity. It plans to pursue stable supply of existing products while expanding new orders through integrated operations between the two production bases.

The company said it will also review further investment, including capacity expansion and technology upgrades at the Rockville facility, based on mid- to long-term demand and utilization.

“This represents a meaningful step in expanding our U.S. manufacturing footprint,” said John Rim, president and chief executive officer of Samsung Biologics. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network.”

By Wang Hae-na and Chang Iou-chung
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]

Source link

Samsung Biologics completes acquisition of US manufacturing facility

Officials cut a ceremonial ribbon during an event marking Samsung Biologics’ acquisition of a biopharmaceutical manufacturing plant in Rockville, Md., Tuesday (local time). From front row fifth from left, are Korean Ambassador to the United States Kang Kyung-wha, Samsung Biologics CEO John Rim, Maryland Gov. Wes Moore and Congresswoman April Delaney. Courtesy of Samsung Biologics

Samsung Biologics has closed the deal to acquire GSK’s facility in Rockville, Md., establishing the biopharmaceutical firm’s first manufacturing base in the United States, the company said Wednesday.

In its regulatory filing, the Korean company said its wholly owned subsidiary Samsung Biologics America has completed the acquisition of Human Genome Sciences, which owns a drug substance manufacturing facility in the U.S. from GSK for a total of $353.1 million.

Of the amount, $280 million is for the acquisition of the facility and equity, while the remaining $73.1 million was paid for the transfer of inventories and raw materials held by Human Genome Sciences.

The deal’s closure came three months after Samsung Biologics announced the acquisition on Dec. 22 last year, as part of its efforts to mitigate risks stemming from the Trump administration’s tariffs on biopharmaceuticals, as well as to expand its contract drug manufacturing capacity beyond Korea.

Samsung Biologics’ biopharmaceutical manufacturing site in Rockville, Md. / Courtesy of Samsung Biologics

The Rockville site is comprised of two manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales.

The acquisition increased Samsung Biologics’ total global manufacturing capacity to 845,000 liters per year from 785,000 liters.

Despite being one of the world’s largest contract drug manufacturers, Samsung Biologics had been exposed to supply chain risks, as all of its manufacturing facilities were located in Korea prior to the acquisition.

With the acquisition, Samsung Biologics will be able to provide clients with more flexible multi-site manufacturing options in both the U.S. and Korea, strengthening collaboration with North American customers and enhancing its ability to respond to regional changes in the supply environment.

Samsung Biologics said it will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, as well as serving additional contract manufacturing needs. The company plans further investments to expand the site’s capacity and upgrade technologies. It will retain more than 500 employees at the site to ensure operational continuity and stability.

Samsung Biologics CEO John Rim speaks during a ceremony marking the company’s acquisition of a biopharmaceutical manufacturing plant in Rockville, Md., Tuesday (local time). Courtesy of Samsung Biologics

“This represents a meaningful step in expanding our U.S. manufacturing footprint,” Samsung Biologics CEO John Rim said.

“The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network. … The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network.”

Source link

Samsung Biologics looks to scale up U.S. manufacturing in Maryland

Samsung Biologics to establish first U.S. manufacturing base in Maryland

ROCKVILLE, MD—In a major win for Maryland’s life sciences sector, Governor Wes Moore announced this week that South Korea-based Samsung Biologics will open its first United States manufacturing facility in Rockville. The move follows a strategic international trade mission led by the Governor earlier this year to strengthen economic ties with East Asian tech leaders.

Samsung Biologics, the world’s largest contract drug manufacturer, has reached an agreement to acquire a manufacturing campus in Rockville from GSK for $280 million. The facility will serve as a cornerstone for the company’s expansion into the American market, providing a localized hub for the production of critical biologic medicines.

Strengthening the Global Supply Chain

The acquisition secures a site that currently houses two high-standard manufacturing plants with a combined capacity of 60,000 liters. Samsung Biologics plans to not only maintain the current production of existing medicines but also invest in significant technology upgrades and capacity expansions.

By establishing a footprint in Maryland, the company aims to create a more resilient supply chain for life-saving therapeutics, offering clinical and commercial production capabilities on U.S. soil.

Economic Impact and Job Retention

A primary component of the agreement is the preservation of Maryland’s specialized workforce. Samsung Biologics has committed to:

• Retaining more than 500 existing jobs at the Rockville site.
• Creating additional high-skilled positions as production capacity grows.
• Generating new opportunities for local Maryland suppliers.

Governor Moore noted that the deal is a testament to the state’s highly skilled workforce and its status as a premier global bio-cluster. The announcement builds on a record year for Maryland’s biopharmaceutical industry, which recently saw a $2 billion investment from AstraZeneca and the arrival of several other international firms.

Strategic Location in the I-270 Tech Corridor

Montgomery County officials emphasized that Rockville’s proximity to federal institutions like the FDA and the NIH makes it an ideal location for global companies navigating complex regulatory environments. County Executive Marc Elrich described the investment as a robust endorsement of the local ecosystem, which relies on a combination of talent, diversity, and public-private partnerships.

The transition is expected to be finalized following the formal close of the acquisition, with Samsung Biologics integrating the Rockville campus into its global network that already spans five major plants in South Korea.

Please follow and like us:

Source link